Stock Analysis·← Pickers

IMNN

Imunon, Inc.

Imunon, Inc. (IMNN) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 44.8, with 0/3 trend checks passing.

Price
$1.93
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
44.8
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

IMNN with MA50 and MA200

14.9411.638.335.021.7207/3110/2401/2204/1707/15
IMNN2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$2.14-9.76% vs price
MA200
$3.31-41.75% vs price
RSI (14)
44.8Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for IMNN

Imunon, Inc. (IMNN) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $1.93, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 9.8% and below the 200-day moving average by 41.8%.

Momentum and stretch context

IMNN currently has an RSI reading of 44.8, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing IMNN next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Imunon, Inc.

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

Sector
Healthcare
Industry
Biotechnology
CEO
Stacy R. Lindborg
Employees
20
Market cap
$4.9M
Beta
1.95
52-week range
$1.70 – $10.43
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
1 Mar 1999
ISIN
US15117N7012
CUSIP
15117N701
Website
imunon.com
Company profile data from Financial Modeling Prep. IMNN listed on NASDAQ.
Share dilution

IMNN shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
5.0M
Since Jun 2019
+4675.1%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. IMNN28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about IMNN

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.